Regional Stocks
Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Halozyme Therapeutics, Inc. (NQ: HALO)
7.420 USD  -0.030 (-0.40%)
Official Closing Price  /  Updated: 5:20 PM EDT, May 24, 2013  /  Add to My Watchlist      
View: Quote News Research
Press releases about Halozyme Therapeutics, Inc.
 
< Previous 1 2 3 4 5 6 7 8 9 Next >
ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20)
March 06, 2012
- Data Presented at the 2012 Annual Meeting of the American Academy of Allergy Asthma & Immunology (AAAAI) - Read More
from PR Newswire
Halozyme to Host Fourth Quarter and 2011 Year-End Financial Results Conference Call
March 01, 2012
from PR Newswire
2012 Economic Outlook - Report Highlights Halozyme Therapeutics, Inc. and Masimo Corporation
February 27, 2012
from Marketwired News Releases
Halozyme Therapeutics to Present at the CITI 2012 Global Healthcare Conference
February 22, 2012
from PR Newswire
Halozyme Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Stock
February 15, 2012
from PR Newswire
Halozyme Announces Pricing of Public Offering of Common Stock
February 10, 2012
from PR Newswire
Halozyme Announces Proposed Public Offering of Common Stock
February 09, 2012
from PR Newswire
HTI-501 Data Support Commencement of Phase 2 Portion of Clinical Trial
January 31, 2012
Subcutaneous Administration of Conditionally Active Recombinant Human Cathepsin Was Well Tolerated Read More
from PR Newswire
Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
January 04, 2012
from PR Newswire
Halozyme Therapeutics to Present at the Oppenheimer Annual Healthcare Conference on December 13
December 07, 2011
from PR Newswire
ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
December 06, 2011
from PR Newswire
Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
November 07, 2011
Initiated two clinical trials of proprietary product candidates PEGPH20 and HTI-501 Read More
from PR Newswire
Halozyme Therapeutics to Host Third Quarter 2011 Financial Results Conference Call on November 7
November 02, 2011
from PR Newswire
Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
October 27, 2011
Pre-administration of rHuPH20 prior to insulin infusion provides consistent ultrafast absorption and superior post-meal glucose control Read More
from PR Newswire
Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
October 27, 2011
-Data Presented at 2011 EORTC-NCI-ASCO Annual Meeting- Read More
from PR Newswire
Halozyme Therapeutics to Present Data on PEGPH20 at the Upcoming 2011 EORTC-NCI-ASCO Annual Meeting
October 24, 2011
from PR Newswire
Halozyme Announces Positive Results From Phase 2 Ultrafast Insulin Trials in Patients with Type 1 and Type 2 Diabetes
October 21, 2011
PH20-prandial insulin analogs achieve primary HbA1C endpoint with superior management of post-prandial glucose compared to the insulin analogs available today Read More
from PR Newswire
Analyst View, Impact of Global Events - Research Report on Callon Petroleum Company and Halozyme Therapeutics, Inc.
October 19, 2011
from Marketwired News Releases
Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial
October 18, 2011
from PR Newswire
Halozyme Begins Randomized, Controlled Clinical Trial with PEGPH20 in Patients with Advanced Pancreatic Cancer
October 05, 2011
Phase 2 Clinical Trial to Assess Safety, Tolerability and Efficacy of Gemcitabine Combined with PEGPH20 Read More
from PR Newswire
Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
September 28, 2011
Phase 1/2 Clinical Trial to Assess Safety, Tolerability and Pharmacologic Activity of First Conditionally Active Biologic For Aesthetic Indications Read More
from PR Newswire
Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
September 22, 2011
from PR Newswire
ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
September 13, 2011
from PR Newswire
Halozyme Therapeutics to Present at Upcoming Financial Conferences
September 01, 2011
from PR Newswire
Halozyme Therapeutics to Present at the Wedbush 2011 Global Healthcare Conference on August 17
August 12, 2011
from PR Newswire
Halozyme Therapeutics Reports Second Quarter 2011 Financial Results
August 05, 2011
Upfront payments from two new partnerships drive additional revenue and cash flow for the quarter Read More
from PR Newswire
Halozyme Therapeutics to Host Second Quarter 2011 Financial Results Conference Call on August 5
August 01, 2011
from PR Newswire
Baxter and Halozyme Announce Top-Line Results of Phase III Study of HyQ in Patients with Primary Immunodeficiency
July 08, 2011
from Business Wire News Releases
Halozyme's Ultrafast Insulin Demonstrates Reduced Variability of Insulin Absorption for Type 1 Diabetes Patients Using Insulin Pumps
June 24, 2011
Late breaking poster at American Diabetes Association 71st Scientific Sessions confirms previous safety findings and faster-in/faster-out PK profile for combination Aspart-PH20 Read More
from PR Newswire
Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions
June 20, 2011
from PR Newswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here